{"doi":"10.1093/ckj/sfaf075","title":"Changes in body composition and handgrip strength during dapagliflozin administration in patients with chronic kidney disease","abstract":"<jats:title>ABSTRACT</jats:title>\n               <jats:sec>\n                  <jats:title>Background</jats:title>\n                  <jats:p>Dapagliflozin improves renal endpoints; however, concerns exist regarding safety in patients with chronic kidney disease. We examined the effects of dapagliflozin on body composition, handgrip strength, and sarcopenia.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>This prospective observational study included 55 patients with chronic kidney disease (type 2 diabetes, n = 27) treated with dapagliflozin 10 mg/day for 24 weeks. Handgrip strength, bio-impedance analysis-estimated skeletal muscle index, and extracellular water-to-total body water ratio were measured at baseline, 12 weeks, and 24 weeks after dapagliflozin administration. Sarcopenia was diagnosed as reduced handgrip strength (women: &amp;lt;18 kg; men: &amp;lt;28 kg) and decreased skeletal muscle index (women: &amp;lt;5.7 kg/m2; men: &amp;lt;7.0 kg/m2).</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>During dapagliflozin therapy, skeletal muscle index significantly decreased from 7.51 ± 1.36 kg/m2 at baseline to 7.40 ± 1.28 kg/m2 at 12 weeks (P &amp;lt; 0.0001) and 7.32 ± 1.35 kg/m2 at 24 weeks (P &amp;lt; 0.0001). The extracellular water-to-total body water ratio decreased from 0.391 ± 0.012 at baseline to 0.390 ± 0.011 at 12 weeks (P = 0.17) and 0.389 ± 0.010 at 24 weeks (P = 0.002). Conversely, handgrip strength was unchanged from 32.9 ± 12.2 kg at baseline to 34.0 ± 12.1 kg at 12 weeks (P = 0.022) and 33.9 ± 12.4 kg at 24 weeks (P = 0.14). Sarcopenia prevalence did not change during dapagliflozin treatment [10.9% (n = 6) at baseline, 14.5% (n = 8) at 12 weeks, 10.9% (n = 6) at 24 weeks; P = 0.45.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions</jats:title>\n                  <jats:p>During the 24-week dapagliflozin treatment, there was a decrease in skeletal muscle index and extracellular water-to-total body water ratio with unchanged handgrip strength in patients with chronic kidney disease. Sarcopenia prevalence remained constant. Therefore, regarding sarcopenia, short-term dapagliflozin administration might be safe. However, further long-term studies are required to determine the safety of dapagliflozin in these patients.</jats:p>\n               </jats:sec>","journal":"Clinical Kidney Journal","year":2025,"id":613161,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1579424,"name":"Kaoru Noda","orcid":null,"position":1,"is_corresponding":false},{"id":1579425,"name":"Kumiko Yajima","orcid":null,"position":2,"is_corresponding":false},{"id":1579423,"name":"Takahiro Yajima","orcid":"0000-0002-8180-5614","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-08-02T06:52:14.147523Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}